European principles of inhibitor management in patients with haemophilia: implications of new treatment options

• C. Hermans,
• P. L. F. Giangrande,
• B. O’Mahony,
• P. de Kleijn,
• M. Bedford,
• A. Batorova,
• J. Blatný,
• K. Jansone,
• on behalf of the European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)

Affiliations

C. Hermans

Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain)

P. L. F. Giangrande

European Haemophilia Consortium

B. O’Mahony

European Haemophilia Consortium

P. de Kleijn

Department of Rehabilitation, Nursing Science and Sports, University Medical Center Utrecht

M. Bedford

Canterbury Christ Church University

A. Batorova

National Hemophilia Center, Dept. of Hematology and Transfusion Medicine, School of Medicine of Comenius University and University Hospital

J. Blatný

Children’s University Hospital and Masaryk University

K. Jansone

European Haemophilia Consortium

on behalf of the European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD)